Literature DB >> 10758352

Enhanced susceptibility to cocaine- and pentylenetetrazol-induced seizures in prenatally cocaine-treated rats.

A Snyder-Keller1, C Sam, R W Keller.   

Abstract

We previously reported that prenatal cocaine exposure increased susceptibility to cocaine-induced seizures later in life. Here we examine whether this enhanced susceptibility to seizures generalizes to other chemoconvulsants, and whether postnatal cocaine treatment similarly increases susceptibility. Following prenatal cocaine treatment (40 mg/kg; E10-20), both male and female rats were more likely to seize to a dose of 30 mg/kg pentylenetetrazol (PTZ) at 2 months of age, although the severity of the seizures observed was increased only in females. Daily cocaine injections (10-20 mg/kg SC) during the first 10 days after birth also produced effects that were dependent on the sex of the animal. Postnatally cocaine-treated female rats showed no greater incidence of seizures in response to an acute high dose of cocaine, but did exhibit an increased susceptibility to cocaine-kindled seizures. Male, but not female, postnatally cocaine-treated rats were more susceptible to PTZ-induced seizures. The increased susceptibility to seizures induced by two different chemoconvulsants after prenatal cocaine treatment suggests that developmental cocaine exposure, particularly during the second trimester equivalent, alters the balance between excitation and inhibition in the brain.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10758352     DOI: 10.1016/s0892-0362(99)00061-6

Source DB:  PubMed          Journal:  Neurotoxicol Teratol        ISSN: 0892-0362            Impact factor:   3.763


  1 in total

1.  Reversal Learning Deficits Associated with Increased Frontal Cortical Brain-Derived Neurotrophic Factor Tyrosine Kinase B Signaling in a Prenatal Cocaine Exposure Mouse Model.

Authors:  Deirdre M McCarthy; Genevieve A Bell; Elisa N Cannon; Kaly A Mueller; Megan N Huizenga; Ghazaleh Sadri-Vakili; Debra A Fadool; Pradeep G Bhide
Journal:  Dev Neurosci       Date:  2016-12-13       Impact factor: 2.984

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.